References
- Emrainger W, Lang H RM, Emminger-Schmidmeier W, Peters C, Gadner H. Amphotericin B serum levels in pediatric bone marrow transplant recipients. Bone Marrow Transpl. 1991; 7: 95–99
- Hawkins C, Armstrong D. Fungal infections in the immunocompromised host. Clin Haematol. 1984; 13(3)599–630
- Meunier F. New methods for delivery of antifungal agents. Rev Infect Dis. 1989; 11: 1605–1612, Suppl 7
- Lopez-Berestein G, Bodey G P, Frankel L S, Mehta K. Treatment of hepatosplenic candidiasis with liposomal amphotericin B. J Clin Oncol. 1987; 5: 310
- Katz N M, Pierce P F, Anzeck R A, Visner M S, Canter H G, Foegh M L, Pearle D L, Tracy C, Rahman A. Liposomal amphotericin B for treatment of pulmonary aspergillosis in a heart transplant patient. J Heart Transpl. 1990; 9: 14–17
- Tollemar J, Ringden O, Tyden G. Liposomal amphotericin-B (AmBisome)® treatment in solid organ and bone marrow transplant recipients. Efficacy and safety evaluation. Clin Transpl. 1990; 4: 167–175
- Mehta F, Lopez-Berestein G, Hopfer R. Liposomal amphotericin B is toxic to fungal cell but not to mammalian cells. Biochim Biophys Acta. 1984; 770: 230–234